[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ATE424893T1 - Behandlung und vorbeugung von insulin- produzierende zelltransplantatabstossung - Google Patents

Behandlung und vorbeugung von insulin- produzierende zelltransplantatabstossung

Info

Publication number
ATE424893T1
ATE424893T1 AT02754637T AT02754637T ATE424893T1 AT E424893 T1 ATE424893 T1 AT E424893T1 AT 02754637 T AT02754637 T AT 02754637T AT 02754637 T AT02754637 T AT 02754637T AT E424893 T1 ATE424893 T1 AT E424893T1
Authority
AT
Austria
Prior art keywords
producing cell
insulin
prevention
treatment
transplant rejection
Prior art date
Application number
AT02754637T
Other languages
English (en)
Inventor
Philip Lake
Claudy Mullon
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE424893T1 publication Critical patent/ATE424893T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
AT02754637T 2001-06-08 2002-06-07 Behandlung und vorbeugung von insulin- produzierende zelltransplantatabstossung ATE424893T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US29706901P 2001-06-08 2001-06-08

Publications (1)

Publication Number Publication Date
ATE424893T1 true ATE424893T1 (de) 2009-03-15

Family

ID=23144725

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02754637T ATE424893T1 (de) 2001-06-08 2002-06-07 Behandlung und vorbeugung von insulin- produzierende zelltransplantatabstossung

Country Status (18)

Country Link
US (5) US20030003099A1 (de)
EP (1) EP1429845B1 (de)
JP (1) JP4476623B2 (de)
CN (1) CN1524002A (de)
AT (1) ATE424893T1 (de)
AU (1) AU2002320828B2 (de)
BR (1) BR0209319A (de)
CA (1) CA2445605A1 (de)
DE (1) DE60231522D1 (de)
ES (1) ES2322442T3 (de)
IL (1) IL158384A0 (de)
NO (1) NO20035434D0 (de)
NZ (1) NZ529044A (de)
PL (1) PL364359A1 (de)
PT (1) PT1429845E (de)
RU (1) RU2003136730A (de)
WO (1) WO2002100148A2 (de)
ZA (1) ZA200307893B (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002067915A1 (en) * 2001-02-22 2002-09-06 Novartis Ag Use of accelerated lymphocyte homing agents for the manufacture of a medicament for the treatment of delayed graft function
CA2566716C (en) * 2004-05-14 2014-12-23 Alexion Pharmaceuticals, Inc. Prolongation of survival of an allograft by inhibiting complement activity
MX2007000564A (es) * 2004-07-16 2007-03-30 Kyorin Seiyaku Kk Metodo para utilizar efectivamente medicamentos referentes a la prevencion de efectos secundarios.
SG187468A1 (en) * 2004-11-29 2013-02-28 Novartis Ag Dosage regimen of an s1p receptor agonist
AU2006212866A1 (en) * 2005-02-08 2006-08-17 Novartis Ag Antilymphocyte antibody induction by combination of an S1P receptor agonist/modulator and of immunosuppressive drugs
WO2009114735A1 (en) * 2008-03-12 2009-09-17 Loma Linda University Dna vaccines and methods for the prevention of transplantation rejection
US20090191218A1 (en) 2005-05-11 2009-07-30 Fengchun Li DNA Vaccines And Methods For The Prevention Of Transplantation Rejection
ES2348701T3 (es) * 2005-05-11 2010-12-10 Loma Linda University Composiciones y mã‰todos para prevenir y tratar trastornos inflamatorios de mediaciã“n inmune.
ATE524432T1 (de) 2005-12-15 2011-09-15 Mitsubishi Tanabe Pharma Corp Aminverbindung und deren verwendung für medizinische zwecke
RU2445975C2 (ru) * 2006-03-02 2012-03-27 Алексион Фармасьютикалз, Инк. Продление срока выживаемости аллотрансплантата путем ингибирования активности комплемента
AU2007299973B2 (en) * 2006-09-28 2010-10-14 Loma Linda University Apoptotic cell-mediated transfection of mammalian cells with interfering RNA
TW200946105A (en) 2008-02-07 2009-11-16 Kyorin Seiyaku Kk Therapeutic agent or preventive agent for inflammatory bowel disease containing amino alcohol derivative as active ingredient
CN104800208A (zh) 2008-03-17 2015-07-29 埃科特莱茵药品有限公司 选择性s1p1受体激动剂的给药方案
WO2010055027A2 (en) * 2008-11-11 2010-05-20 Novartis Ag Organic compounds
ES2643161T3 (es) * 2008-11-11 2017-11-21 Novartis Ag Formas cristalinas de HCL de fingolimod
EP2455875A3 (de) * 2009-06-30 2013-01-16 Lifescan Scotland Limited System und Verfahren zur Diabetes-Handhabung
EP2448469B1 (de) * 2009-06-30 2021-07-21 Lifescan, Inc. Analyttestverfahren und vorrichtung zur berechnung einer basalinsulintherapie
WO2011041007A1 (en) * 2009-09-29 2011-04-07 Lifescan Scotland Limited Analyte testing method and device for diabetes management
KR101722417B1 (ko) * 2010-02-25 2017-04-03 라이프스캔 스코트랜드 리미티드 고혈당 및 저혈당 경향 통지를 갖는 분석물 검사 방법 및 시스템
WO2013044177A2 (en) 2011-09-23 2013-03-28 Loma Linda University Bacterial strains expressing methylase genes and uses thereof
US11680273B2 (en) 2011-09-23 2023-06-20 Loma Linda University Treatment of autoimmune diseases
CN114306643A (zh) * 2021-11-30 2022-04-12 中国科学院昆明动物研究所 一种恒河猴免疫抑制模型的构建方法及在car-t细胞植活上的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122011100012I1 (de) * 1992-10-21 2011-10-20 Mitsubishi Tanabe Pharma Corp 2-Amino-1, 3-propandiolverbindung und immunosuppressium.
US5679546A (en) * 1993-09-24 1997-10-21 Cytomed, Inc. Chimeric proteins which block complement activation
JPH09510088A (ja) * 1994-03-03 1997-10-14 アレクション・ファーマシューティカル・インク 最終補体インヒビター融合遺伝子およびタンパク質
GB9624038D0 (en) * 1996-11-19 1997-01-08 Sandoz Ltd Organic compounds
JPH1180026A (ja) * 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
WO2002067915A1 (en) * 2001-02-22 2002-09-06 Novartis Ag Use of accelerated lymphocyte homing agents for the manufacture of a medicament for the treatment of delayed graft function

Also Published As

Publication number Publication date
AU2002320828B2 (en) 2006-02-02
RU2003136730A (ru) 2005-05-20
WO2002100148A3 (en) 2004-04-22
EP1429845B1 (de) 2009-03-11
WO2002100148A2 (en) 2002-12-19
US20110236382A1 (en) 2011-09-29
US20080199465A1 (en) 2008-08-21
JP4476623B2 (ja) 2010-06-09
NO20035434D0 (no) 2003-12-05
JP2004534788A (ja) 2004-11-18
ZA200307893B (en) 2004-09-06
EP1429845A2 (de) 2004-06-23
NZ529044A (en) 2008-03-28
PT1429845E (pt) 2009-06-15
US20030003099A1 (en) 2003-01-02
PL364359A1 (en) 2004-12-13
US20060153842A1 (en) 2006-07-13
IL158384A0 (en) 2004-05-12
BR0209319A (pt) 2004-07-20
CN1524002A (zh) 2004-08-25
ES2322442T3 (es) 2009-06-22
DE60231522D1 (de) 2009-04-23
US20140093502A1 (en) 2014-04-03
CA2445605A1 (en) 2002-12-19

Similar Documents

Publication Publication Date Title
ATE424893T1 (de) Behandlung und vorbeugung von insulin- produzierende zelltransplantatabstossung
TNSN00010A1 (fr) DIPHENYLUREE A SUBSTITUTION ω CARBOXYARYLE SERVANT D'INHIBUTEURS DE RAF KINASE.
YU46200A (sh) N-(supstituisani peto-članog di-ili triaza dinezasićenog prstena)karbonil/guanidin derivati za tretiranje ishemije
FR2757520B1 (fr) Derive de cyclosporine, sa preparation et les compositions pharmaceutiques qui le contiennent
NL300056I1 (nl) Toepassing van rapamycine en derivaten en vóórgeneesmiddelen daarvan bij de bereiding van een geneesmiddel voor het remmen van de afstoting van een transplantaat in zoogdieren.
JO1613B1 (en) Derivatives of n - (3-hydroxy-4-piperidnil) dihydrobenzofuran, dihydro-2u-benzopyran or dihydro-benzodoxine) carboxymide
FR2757522B1 (fr) Derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
TR199701567T1 (xx) Rapamisin t�revleri.
ATE293995T1 (de) Pharmazeutische zusammensetzungen, die wirkstoffabsorptionsfördernde verbindungen enthalten
FR2757521B1 (fr) Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
DK1039912T3 (da) Angiostatiske midler og præparater til behandling af GLC1A-glaukom
ATE240115T1 (de) Zusammensetzung zur vorbeugung und/oder behandlung der atherosklerose
WO2004031129A3 (en) Compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection
UA35567C2 (uk) Фармацевтичний препарат для лікування хворих з порушеннями функції коагуляції, спосіб лікування таких хворих, спосіб одержання фармацевтичного препарату
ATE481104T1 (de) Mittel zur behandlung von flaviviridae- infektionen
EA200200207A1 (ru) Применение антагонистов cgrp и ингибиторов высвобождения cgrp для устранения приливов в период менопаузы
WO2001078653A3 (en) Graft rejection inhibition with ccr2 inhibitors
DE59813162D1 (de) Pharmazeutische zusammensetzung enthaltend clindamycin und clotrimazol, zur behandlung vaginaler infektionen
NZ330944A (en) Peptide derivatives
ATE245444T1 (de) Pharmazeutische zusammensetzung, enthaltend peg- asparaginase, für die behandlung von hiv infektionen
DK1147105T3 (da) Optisk aktivt pyridyl-4H-1,2,4-oxadiazinderivat og anvendelse af dette til behandling af karsygdomme
ATE216891T1 (de) Verwendung von immunosuppressiva zur behandlung der schizophrenie
ATE254595T1 (de) 2-amino-6-methyl-7-acetyl-tetralin und pharmazeutische zusammensetzungen zur vorbeugung und therapeutischen behandlung von entzündlichen und/oder autoimmunkrankheiten
ES2190581T3 (es) 2-aminotetralina opticamente activa, procedimiento para su preparacion y composiciones farmaceuticas que la contienen, activa en la prevencion y tratamiento de shock septico.
DE60120986D1 (de) Nicht-peptidische ccr1 rezeptor-antagonisten in kombination mit cyclosporin a zur behandlung von herztransplantatabstossung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1429845

Country of ref document: EP